The SAVI SCOUT surgical guidance system has been adopted by hospitals throughout the country. Brought to you by the same team behind the SAVI brachytherapy applicator, SCOUT® is a FDA-cleared medical device used to provide tumor localization and real-time guidance during breast surgery.
If you would like to be kept up to date on the latest information and updates regarding SCOUT, including details on clinical experience and product availability, you are invited to join the SCOUT Report® community.
In This Issue
BrachyBytes Editorial Advisory Board

Robert Kuske, M.D.

Jay Reiff, Ph.D.
Dan Scanderbeg, Ph.D.
Catheryn Yashar, M.D.
Vic Zannis, M.D.
Upcoming Events



Brachytherapy GEC-ESTRO Highlights Webinar


Dr. Vicini


November 11, 2015
Moving Beyond Wires Webinar
Dr. Pat Whitworth
November 18, 2015

Become a Center of Excellence in APBI!

Learn about becoming a Center of Excellence and find ways to grow your APBI program by reaching out to referring physicians and women in the community.

Contact for more information.
Follow-up Links

Past Issues

Cianna Medical

SAVI Sisters

November 2015

New Data Presented at ASTRO 2015 and Published in The Lancet Demonstrate that Accelerated Partial Breast Irradiation with Brachytherapy Achieves Favorable Long-Term Efficacy Equivalent to Traditional Whole Breast Irradiation 

Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.

A Perspective from Frank Vicini, MD

Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines shares his views on the new data.
How might these data potentially impact current clinical practice?
I believe these data have the ability to impact clinical practice. As women learn about the potential advantages of APBI, they will undoubtedly request it. ASTRO announced at the annual meeting a reduction in the age limit for suitable candidates from APBI from 60 to 50 years of age. This is a significant change and the guidelines will go out for commentary this December 2015.
The GEC-ESTRO trial used interstitial multicatheter brachytherapy which is not commonly performed in the United States. Do you expect divergent clinical outcomes with this procedure vs. single entry, strut-based brachytherapy?
In the States, other forms of brachytherapy, such as strut-based, inter-cavity devices are used to deliver radiation. There is no reason to believe that these devices cannot produce the same results as the ones shown in the GEC -ESTRO trial. As long as the radiation is covering the same target area around the tumor bed and delivering that dose safely one should expect the same results as interstitial brachytherapy.
Now that a sizable body of solid clinical evidence exists to support the use of accelerated treatment with brachytherapy, what does the future hold?
I believe we will continue to see shorter periods of radiation treatment for appropriately selected patients. In fact, the GEC-ESTRO data used 7 to 8 fractions (instead of the commonly used 10). A trial known as the “TRI-fraction Radiotherapy Utilized to Minimize Patient Hospital Trips” (TRIUMPH-T) is underway to explore the efficacy of treating patients with radiation delivered over a shortened period of only two to three days. Researchers expect that results from TRIUMPH-T will confirm a similar previous study by the Cancer Institute of New Jersey where researchers showed the approach of giving radiation therapy over a two day period was safe.


APBI with Brachytherapy Proven to be as Effective as Whole Breast Radiation

Presented by Dr. Frank Vicini, M.D.
Join us for an educational webinar Wednesday, November 11, 2015 to hear highlights from the landmark GEC-ESTRO APBI trial, the first prospective, randomized, multicenter Phase 3 trial comparing breast brachytherapy to whole breast irradiation. The results were presented at ASTRO 2015 and published in The Lancet. Learn how this milestone data can impact your practice.
To register, please visit